Botulinum toxin type A in the treatment of laryngeal dystonia: a single-center experience

Remigiusz Ziarno; Małgorzata Dec-Ćwiek; Magdalena Sobuś; Konrad Skórkiewicz; Aleksandra Grudzień-Ziarno; Jacek Składzień; Jerzy Tomik

doi:10.20883/medical.e889

Authors

Remigiusz Ziarno Clinical Department of Otolaryngology, University Hospital of Cracow, Cracow, Poland; Jagiellonian University Medical College, Cracow, Poland https://orcid.org/0000-0002-0765-9700
Małgorzata Dec-Ćwiek Clinical Department of Neurology, University Hospital of Cracow, Poland https://orcid.org/0000-0002-9829-3301
Magdalena Sobuś Veterinary Medicine Clinic, Nicolaus Copernicus University in Toruń, Poland https://orcid.org/0009-0008-5908-0435
Konrad Skórkiewicz Department of Biophysics, Faculty of Medicine, Jagiellonian University Medical College, Cracow, Poland https://orcid.org/0000-0002-0362-4500
Aleksandra Grudzień-Ziarno Clinical Department of Otolaryngology, University Hospital of Cracow, Cracow, Poland
Jacek Składzień Jagiellonian University Medical College, Cracow, Poland https://orcid.org/0000-0003-4778-1281
Jerzy Tomik Clinical Department of Otolaryngology, University Hospital of Cracow, Cracow, Poland https://orcid.org/0000-0003-2440-6497

DOI:

https://doi.org/10.20883/medical.e889

Keywords:

larynx, neurology, dystonia, toxin, videolaryngostroboscopy

Abstract

Aim. The aim of this study was the analysis of the problem of laryngeal dystonia in patients of Otolaryngology and Neurology Clinics to assess the efficiency of effects of Botulin Toxin type A (BOTOX^tm) injections on voice quality and function of vocal cords with the use of videolaryngostroboscopic and laryngographic examinations, GRBAS (G - grade of hoarseness, R - roughness, B - breathiness, A – aesthenia, S -strain) scale and voice field.

Material and methods. Between 2020 and 2022 a total of 50 patients with laryngeal dystonia were examined. The videolaryngostroboscopic and laryngographic examinations confirmed laryngeal dystonia. Afterwards the patients undertook Botulinum Toxin type A injections into the thyro-arythenoid muscle.

Results. Control examinations confirmed the improvement of vocal folds movability and the decrease in number of irregular vocal folds vibrations. The next injection of BOTOX^tm substance was done 3-6 months after the last injection.

Conclusion. The results of our study suggest that although BOTOX^tm toxin still remains the main form of treatment for laryngeal dystonia, using it improves phonatory function of larynx (as proven by videolaryngostroboscopic examination).

Downloads

Download data is not yet available.

References

Richter A, Hamann M, Wissel J, Volk HA: Dystonia and Paroxysmal Dyskinesias: Under-Recognized Movement Disorders in Domestic Animals? A Comparison with Human Dystonia/Paroxysmal Dyskinesias. Front Vet Sci, 2015 Nov 30;2:65. doi: 10.3389/fvets.2015.00065.

Albanese A, Bhatia K, Bressman SB, DeLong MR, Fahn S, Fung VSC i wsp: Phenomenology and Classification of Dystonia: A Consensus Update. Movement Disorders, 2013 Jun 15;28(7):863-73. doi: 10.1002/mds.25475.

Evinger C: Animal models of focal dystonia. NeuroRx. 2005 Jul;2:513-24. doi: 10.1602/neurorx.2.3.513.

Castelon Konkiewitz E, Trender-Gerhard I, Kamm C, Warner T, Ben-Shlomo Y, Gasser T, Conrad B, Ceballos-Baumann AO: Service-based survey of dystonia in Munich. Neuroepidemiology. 2002 Jul-Aug;21:202-6. doi: 10.1159/000059525.

McCall Jr., Stringhalt” and shivering. Proceedings 28th General Meeting of the National Veterinary Association (1910): 23–56. doi: 10.1016/j.tvjl.2022.105829.

Blitzer A: Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series. Eur J Neurol, 2010 Jul;17 Suppl 1:28-30. doi: 10.1111/j.1468-1331.2010.03047.x.

Blitzer A, Brin MF, Simonyan K., Ozelius LJ, Frucht SJ: Phenomenology, Genetics and CNS network abnormalities in Laryngeal Dystonia: a 30 year experience. Laryngoscope, 2018;128 Suppl 1:S1–S9. doi: 10.1002/lary.27003. Epub 2017 Dec 8.

Santos VJB, Mattioli FM, Mattioli WM, Daniel RJ, Vicente Paulo Miranda Cruz VPM: Laryngeal dystonia: case report and treatment with botulinum toxin. Rev Bras Otorrinolaringol 2006;72:425-7. doi: 10.1016/s1808-8694(15)30980-0.

Janczewski G: Otorynolaryngologia praktyczna, podręcznik dla studentów i lekarzy, tom II pod redakcją Grzegorza Janczewskiego. Via Medica, Gdańsk 2005, wyd. 1.

De Biase NG; De Lima Pontes PA; Santos Junior V; Vieira VP; Zambonato P; Yazaki RK: The difficult management of patients with respiratory segmental dystonia. Braz J Otorhinolaryngol, 2007 Mar-Apr;73:278-83. doi: 10.1016/s1808-8694(15)31078-8.

Zbrojkiewicz M, Lebiedowska A, Błońska-Fajfrowska B: Toksyna botulinowa w medycynie i kosmetologii – dwustuletnia historia i nowe perspektywy. Postepy Hig Med Dosw (online), 2018; 72: 278-289. e-ISSN 1732-2693.

Kartha N: Wyzwania terapeutyczne w leczeniu dystonii. Neurologia po Dyplomie, Tom 5 Nr 6 2010, 45-54.

Meyer-Lindberg A., Wohlfarth KM, Switzer EN. The use of botulinum toxin A for treatment of possible essential blepharospasm in a dog. Aust Vet J (2003) 81: 612–4. doi: 10.1111/j.1751-0813.2003.tb12503.x.

Namin AW, Christopher KM, Eisenbeis JF: Botulinum Toxin Dosing Trends in Spasmodic Dysphonia Over a 20-year Period. J Voice, 2017 Jan;31:107-110. doi: 10.1016/j.jvoice.2016.01.006. .

Upile T, Elmiyeh B, Jerjes W, Prasad V, Kafas P, Abiola J, Youl B, Epstein R, Hopper C, Sudhoff H, Rubin J. Unilateral versus bilateral thyroarytenoid Botulinum toxin injections in adductor spasmodic dysphonia: a prospective study. Head Face Med. 2009 Oct 24;5:20. doi: 10.1186/1746-160X-5-20.

Halstead LA, McBroom DM, Bonilha HS: Task-specific singing dystonia: vocal instability that technique cannot fix. J Voice. 2015 Jan;29:71-8. Epub 2014 Jul 5. doi: 10.1016/j.jvoice.2014.04.011.

Payne S, Tisch S, Cole I, Brake H, Rough J, Darveniza P: The clinical spectrum of laryngeal dystonia includes dystonic cough: observations of a large series. Mov Disord. 2014 May; 29:729-35. doi: 10.1002/mds.25865.

Cook WR: A comparison of idiopathic laryngeal paralysis in man and horse. J Laryngol Otol, 1970 Aug;84:819-35

Green DC, Berke GS. An in vivo canine model for testing treatment effects in laryngeal hyperadduction disorders. Laryngoscope. 1990 Nov;100(11):1229-35. doi: 10.1288/00005537-199011000-00019.

Novakovic D, Waters HH, D'Elia JB, Blitzer A. Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes. Laryngoscope. 2011 Mar;121(3):606-12. doi: 10.1002/lary.21395.

Berke GS, Blackwell KE, Gerratt BR, Verneil A, Jackson KS, Sercarz JA. Selective laryngeal adductor denervation-reinnervation: A new surgical treatment for adductor spasmodic dysphonia. Ann Otol Rhinol Laryngol 1999;108: 227–231. doi: 10.1177/000348949910800302.

Mor N, Blitzer A: Diagnosis and Treatment of Laryngeal Dystonia: Past, Present and Future Directions. Tremor and Other Hyperkinetic Movements 2016.

Stewart CF, Sinclair CF, Kling IF, Diamond BE, Blitzer A: Adductor focal laryngeal Dystonia: correlation between clinicians’ ratings and subjects’ perception of dysphonia. Stewart et al. Journal of Clinical Movement Disorders (2017) 4:20. doi: 10.1186/s40734-017-0066-y.

Koufman JA, Blalock PD. Classification of laryngeal dystonias - Center for Voice Disorders of Wake Forest University 2003.

Niebudek-Bogusz E i wsp. Rehabilitacja zawodowych zaburzeń głosu. Poradnik dla nauczycieli. Publikacja współfinansowana przez Unię Europejską w ramach Europejskiego Funduszu Społecznego. Instytut Medycyny Pracy im. prof. J. Nofera. Łódź 2009.

Niebudek-Bogusz E, Modzelewska-Radwan B, Pietruszewska W, Zielińska M, Gryczyński M. Trudności diagnostyczne i terapeutyczne w dystoniach krtaniowych. Otolaryngologia Polska, 2003;57:739-745.

Zbrojkiewicz M, Lebiedowska A, Błońska-Fajfrowska B. Toksyna botulinowa w medycynie i kosmetologii – dwustuletnia historia i nowe perspektywy. Postepy Hig Med Dosw (online), 2018; 72: 278-289.

Enver N, Pitman MJ. What Is New in Laryngeal Dystonia: Review of Novel Findings of Pathophysiology and Novel Treatment Options. Curr Otorhinolaryngol Rep 8, 209–215 (2020). https://doi.org/10.1007/s40136-020-00301-x.

Khosravani, S., Mahnan, A., Yeh, IL. et al. Laryngeal vibration as a non-invasive neuromodulation therapy for spasmodic dysphonia. Sci Rep 9, 17955 (2019). doi: 10.1038/s41598-019-54396-4.

Tierney WS, Bryson PC, Nelson R, Kaplan SE, Benninger MS, Milstein CF. Respiratory Laryngeal Dystonia: Characterization and Diagnosis of a Rare Neurogenic Disorder. Laryngoscope. 2020 Dec;130:2843-2846, Epub 2020 Feb 19. doi: 10.1002/lary.28559.

Flatau E., Sterling W. Progressiver Torsionspasms bei Kindern. Zeitschrift für die Gesamte Neurologie und Psychiatrie 7, 586–612, 1911.

Hirano, M. Clinical examination of voice. Wien-New-York: Springer-Verlag, 1981.

Smith M.E., Ford Ch.N. Resistance to Botulinum Toxin Injections for Spasmoid Dysphonia. Arch Otolaryngol Head Neck Surg/Vol 126, Apr 2000. doi: 10.1001/archotol.126.4.533.

Yeung W, Richards AL, Novakovic D. Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia. Toxins (Basel). 2022 Dec 1;14(12):844. doi: 10.3390/toxins14120844.

Yao D, O'Flynn LC, Simonyan K. DystoniaBoTXNet: Novel Neural Network Biomarker of Botulinum Toxin Efficacy in Isolated Dystonia. Ann Neurol. 2023 Mar;93(3):460-471. doi: 10.1002/ana.26558.

Stachler RJ, Francis DO, Schwartz SR, Damask CC, Digoy GP, Krouse HJ, McCoy SJ, Ouellette DR, Patel RR, Reavis CCW, Smith LJ, Smith M, Strode SW, Woo P, Nnacheta LC. Clinical Practice Guideline: Hoarseness (Dysphonia) (Update) Executive Summary. Otolaryngol Head Neck Surg. 2018 Mar;158(3):409-426. doi: 10.1177/0194599817751031. Erratum in: Otolaryngol Head Neck Surg. 2018 Aug;159(2):403.